Cargando…

Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer

The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis,...

Descripción completa

Detalles Bibliográficos
Autores principales: Fakih, M., Vincent, M.
Formato: Texto
Lenguaje:English
Publicado: Multimed Inc. 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901793/
https://www.ncbi.nlm.nih.gov/pubmed/20680104
_version_ 1782183710209081344
author Fakih, M.
Vincent, M.
author_facet Fakih, M.
Vincent, M.
author_sort Fakih, M.
collection PubMed
description The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC.
format Text
id pubmed-2901793
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Multimed Inc.
record_format MEDLINE/PubMed
spelling pubmed-29017932010-08-02 Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer Fakih, M. Vincent, M. Curr Oncol Medical Oncology The epidermal growth factor receptor (EGFR), a member of the ErbB family of receptor tyrosine kinases, plays an important role in the control of cell growth and differentiation. Disruption of its signaling leads to neoplastic cell proliferation, migration, stromal invasion, resistance to apoptosis, and angiogenesis. EGFR is overexpressed in a variety of solid tumors, including colorectal cancer (CRC), and its overexpression is associated with poorer prognosis. One class of agents that is currently used to target EGFR in the treatment of metastatic CRC (mCRC) is the monoclonal antibodies. While the monoclonal antibody EGFR inhibitors lack many of the severe side effects commonly observed with cytotoxic chemotherapy, they are associated with a set of unique dermatological toxicities. This paper reviews the safety profile of the anti-EGFR monoclonal antibodies cetuximab and panitumumab in the treatment of mCRC. Multimed Inc. 2010-07 /pmc/articles/PMC2901793/ /pubmed/20680104 Text en 2010 Multimed Inc. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Medical Oncology
Fakih, M.
Vincent, M.
Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
title Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
title_full Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
title_fullStr Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
title_full_unstemmed Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
title_short Adverse events associated with anti-EGFR therapies for the treatment of metastatic colorectal cancer
title_sort adverse events associated with anti-egfr therapies for the treatment of metastatic colorectal cancer
topic Medical Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2901793/
https://www.ncbi.nlm.nih.gov/pubmed/20680104
work_keys_str_mv AT fakihm adverseeventsassociatedwithantiegfrtherapiesforthetreatmentofmetastaticcolorectalcancer
AT vincentm adverseeventsassociatedwithantiegfrtherapiesforthetreatmentofmetastaticcolorectalcancer